Guided Therapeutics, Inc.
GTHP
$0.29
$0.000.00%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -96.88% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -96.88% | -- | -- |
| Cost of Revenue | -- | -- | -81.25% | -- | -- |
| Gross Profit | -- | -- | -112.50% | -- | -- |
| SG&A Expenses | 63.74% | 10.03% | 220.91% | -18.18% | -70.14% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.35% | 13.42% | 340.77% | -9.95% | -57.71% |
| Operating Income | -16.49% | -15.32% | -310.07% | 9.95% | 56.48% |
| Income Before Tax | -14.39% | -6.22% | -68.91% | 3.40% | 54.46% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -14.39% | -6.22% | -68.91% | 3.40% | 54.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.39% | -6.22% | -68.91% | 3.40% | 54.46% |
| EBIT | -16.49% | -15.32% | -310.07% | 9.95% | 56.48% |
| EBITDA | -16.56% | -15.41% | -307.65% | 9.98% | 56.59% |
| EPS Basic | 19.26% | 16.05% | -28.09% | 12.95% | 57.14% |
| Normalized Basic EPS | 19.75% | 20.83% | -351.85% | 13.10% | 58.03% |
| EPS Diluted | 19.26% | 0.00% | -116.85% | 12.95% | 57.14% |
| Normalized Diluted EPS | 19.75% | 20.83% | -351.85% | 13.10% | 58.03% |
| Average Basic Shares Outstanding | 40.82% | 24.73% | 16.70% | 10.81% | 9.84% |
| Average Diluted Shares Outstanding | 40.82% | 24.73% | 16.70% | 10.81% | 9.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |